FindTrial
Sign In

Construction and Clinical Decision Impact Assessment of an Intelligent Prediction System for Occult Lymph Node Metastasis in Lung Cancer Based on Multicenter CT Imaging and Human-Machine Collaborative Image Interpretation

Construction and Clinical Decision Impact Assessment of an Intelligent Prediction System for Occult Lymph Node Metastasis in Lung Cancer Based on Multicenter CT Imaging and Human-Machine Collaborative Image Interpretation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600125534
Enrollment
Unknown
Registered
2026-05-28
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer (NSCLC)

Interventions

Occult Lymph Node Metastasis Group (OLNM Group):None
Lymph Node Negative Group (N0 Group):None

Sponsors

Army Medical Center of PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-90 years. 2. Preoperative clinical staging of cT1a-T2aN0M0 according to the 8th edition of the Union for International Cancer Control (UICC) TNM staging system. 3. High-resolution computed tomography (HRCT) of the chest with thin-slice acquisition (slice thickness =2.5mm) performed within 1 month prior to surgery, either non-contrast or contrast-enhanced, without significant respiratory motion artifacts, with complete and available DICOM data. 4. CT imaging demonstrates target lesions as solid nodules or part-solid nodules with predominant solid component (>25%), without radiological evidence of hilar or mediastinal lymph nodes with short-axis diameter >10mm or fusion. 5. Underwent anatomical lobectomy or segmentectomy with concurrent systematic lymph node dissection (e.g., right side: stations 2R, 4R, 7, 9, 11; left side: stations 5, 6, 7, 9, 11) or standardized lymph node sampling (at least 3 stations, including station 7). 6. Postoperative paraffin pathology confirmed as primary invasive lung adenocarcinoma.

Exclusion criteria

Exclusion criteria: 1.Received neoadjuvant therapy (chemotherapy, immunotherapy, targeted therapy, or radiotherapy) prior to surgery. 2.Preoperative examination revealed distant metastasis (M1) or history of other malignancies (except for multiple primary lung cancers). 3.Postoperative pathology confirmed as adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), or pure ground-glass opacity (pGGO). 4.Incomplete clinical records (particularly regarding the number of lymph node stations and nodes dissected).

Design outcomes

Primary

MeasureTime frame
Area Under the Receiver Operating Characteristic Curve (AUC);Accuracy improvement value;—

Secondary

MeasureTime frame
Net Reclassification Index (NRI);Time spent on reading a single case;—

Countries

China

Contacts

Public ContactDeng Bo

Army Medical Center of PLA

superdb@163.com+86 13637782166

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026